The present state of aspirin and clopidogrel resistance

Hamostaseologie

Volumn 29, Issue 3, 2009, Pages 285-290

  Guyer, Kirk E ^a  

^a INDIANA UNIVERSITY SOUTH BEND   (United States)

Author keywords

Aspirin; Clopidogrel; Monitoring; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MONOTHERAPY; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT IDENTIFICATION; RESTENOSIS; REVIEW; RISK ASSESSMENT; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 68549107762     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617036     Document Type: Review

References (53)

1. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86. (Pubitemid 34073138)
2. Awtry E, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
3. Becker R, Moliterno D, Jennings L et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
4. Bedossa M, Letocart V, Gueret P. Incidence of true clopidogrel resistance in high-risk percutaneous coronary intervention patients using VASP test. J Car Rev 2008; 9: 111.
5. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
6. Bhatt DL, Topol EJ, CHARISMA Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the CHARISMA trial. Am Heart J 2004; 148: 263-268.
7. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
8. Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317. (Pubitemid 46891710)
9. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P4503A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59.
10. Eikelboom JW, Hankey GJ, Thom J et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
11. Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin-resistant Thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655. (Pubitemid 34298607)
12. Grines C, Bonow R, Casey D et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007; 115: 813-818.
13. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965. (Pubitemid 36315537)
14. Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826. (Pubitemid 41579802)
15. Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832. (Pubitemid 41579803)
16. Ho P, Maddox T, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
17. Hulot J-S, Bura A,Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247
18. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979; 63: 532-535.
19. Krasopoulos G, Brister SJ, Beattie WS et al. Aspirin " resistance" and risk of cardiovascular morbidity: systemic review and meta-analysis. Br Med J 2008; 336: 195-198. (Pubitemid 351212675)
20. Lopez AD, Murray CCJL. The global burden of disease. Nat Med 1998; 4: 1241-1243.
21. Mancini JA, O'Neill GP, Bayly C, Vickers PJ. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett 1994; 342: 33-37. (Pubitemid 24101388)
22. Maree AO, Curtin RJ, Chubb A et al. Cyclooxygenase- 1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345. (Pubitemid 41727215)
23. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-1181.
24. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46: 986-993.
25. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
26. McAdam BF, Catella-Lawson F, Mardini IA et al. Systemic biosynthesis of prostacyclin by cyclooxygenase- 2. The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
27. O'Neill G, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-1130 (Pubitemid 23265121)
28. Patrono C, Bachman F, Baigent C et al. Expert Consensus Document on the Use of Antiplatelet Agents. Eur Heart J 2004; 25: 166-181.
29. Patrono C, García Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
30. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-1672.
31. Reilly IA, Doran JB, Smith B, Fitzgerald DJ. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300-1309. (Pubitemid 16080544)
32. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
33. Rocca B, Secchiero P, Ciabattoni G et al. Cycloxygenase- 2 expression is induced during human megakaryopoieses and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639. (Pubitemid 34568743)
34. Sanderson S, EmeryJ, Baglin T et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380. (Pubitemid 40293410)
35. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets, I: acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632.
36. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
37. Samuelsson B, Granström E, Green K et al. Prosta - glandins. Ann Rev Biochem 1975; 44: 669-695.
38. Sanderson S, EmeryJ, Baglin T et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380. (Pubitemid 40293410)
39. Santilli F, Rocca B, De Cristofaro R et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. JACC 2009; 53: 667-677.
40. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Comm 2001; 283: 379-383.
41. Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896. (Pubitemid 30946954)
42. Schonbeck U, Sukhova GK, Graber P et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291. (Pubitemid 29488935)
43. Schwartz K, Schwartz D, Ghosheh K et al. Compliance as critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975. (Pubitemid 40487749)
44. Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with pointof- care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
45. Snoep JD, Hovens MM, Eikenboom JC et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: as systemic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
46. Spear BB, Heath-Chiozzi M, Huff J et al. Clinical application of pharmacogenetics. Trends Mol Med 2002; 7: 201-204.
47. Spertus J, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809. (Pubitemid 44305292)
48. Tantry U, Bliden K, Gurbel P. Overestimation of platelet aspirin resistance detection by thrombo - elastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. JACC 2005; 49: 1705-1709. (Pubitemid 41531626)
49. Tran H, Anand S, Hankey G, Eikelboom J. Aspirin resistance. Thromb Res 2007; 120: 337-346.
50. Weber AA, Zimmerman KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900. (Pubitemid 29126885)
51. Weiss HJ. Discovery of the antiplatelet effect of aspirin: a personal reminiscence. J Thromb Haemost 2003; 1: 1869-1875.
52. Wiviott S, Braunwald E, McCabe C et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2008; 357: 2001-2015.
53. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)